The global 3D cell culture market is projected to reach USD 1,720.3 million by 2022 from USD 682.8 million in 2017, at a CAGR of 20.3% during the forecast period. The market growth is majorly driven by factors, such as the rising focus on developing alternative methods for animal testing, funding initiatives from government and private investors, technological advancements and new product launches, and growing awareness. On the other hand, lack of infrastructure for 3D cell-based research is likely to limit the growth of the 3D cell culture market during the forecast period.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191072847
How emergence of microfluidics-based 3D cell culture is an opportunity?
Recent advances have enabled the use of microfluidics in 3D cell culture to develop microenvironments that support tissue differentiation and replicate the tissue-tissue interface, spatiotemporal chemical gradients, and mechanical microenvironments of living organs. This organ-on-a-chip model enables the study of human physiology in an organ-specific context, which allows the development of in vitro disease models and eventually serves as a replacement for animal models in drug development and toxicity testing.
Given its potential, a number of research studies are being conducted to evaluate the performance of microfluidic chips in pharmaceutical studies. For instance, in December 2015, Emulate (US) extended its research collaboration with Merck. This research will focus on using Emulate’s small airway lung-chip and intestine-chip to enable the predictive modeling of inflammation in lung and gastrointestinal diseases. Additionally, in June 2015, Emulate collaborated with Janssen Biotech to use Emulate’s organ-on-a-chip model to predict potential human responses in drug development. The increasing applications of microfluidics in 3D cell culture will offer an array of opportunities for the growth of the market.
What are the challenges caused by lack of consistency in 3D cell culture products?
The use of scaffold-based 3D cell cultures has extended the range of research opportunities. However, the presence of multiple growth factors in scaffolds leads to their batch-to-batch variability, which interferes with the biological studies of signaling pathways and pharmacological investigations. To overcome this difficulty, growth-factor-reduced scaffolds have been developed, such as Matrigel Matrix (Corning). Although the cells grown upon scaffolds with reduced growth factors displayed phenotypes similar to that of cells grown upon high-growth-factor scaffolds, the proliferation rate was very high.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=191072847
In addition, cells grown on low-growth-factor scaffolds cannot be approved for human implantation. This highlights the need for materials offering the natural functionality of ECM and the capability to specify biological and material properties. Scaffolds made of synthetic materials, such as synthetic peptides, are anticipated to address this obstacle in the near future; however, until their introduction, the lack of consistency will continue to remain a key market challenge.
Browse Related Reports:
Organs-on-chips Market by Type (Liver, Kidney, Lung, Heart, Intestines, Gut), Offering (Product, Service), Application (Toxicity testing, Physiological model), End User (Academic, Research Institute, Pharma companies) – Global Forecast to 2022
Cell Analysis Market by Product [Microscope, Spectrophotometers, Flow cytometry (Software, Accessories)], Process (Cell Viability, Cell Proliferation, Signal Transduction), End User (Pharma, Research, Biotechnology Companies) – Global Forecast to 2024
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Media Contact
Company Name: MarketsandMarkets
Contact Person: Mr. Shelly Singh
Email: Send Email
Phone: 1-888-600-6441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/3d-cell-culture-market-191072847.html